Announcements
Sidley Represents Nektar Therapeutics in Its Sale of Its Manufacturing Facility and Reagent Supply Business
November 4, 2024
Sidley is representing Nektar Therapeutics in its US$90 million sale of its manufacturing facility and reagent supply business to Ampersand Capital Partners. The sale will help to streamline Nektar Therapeutics’ future operations as it looks to expand its development of core research and development programs in immunology.
The Sidley team is being led by Daniel J. Belke and Tommy Tsao (M&A and Private Equity) and Joshua T. Hofheimer and Lauren G. Grau (Technology and Life Sciences Transactions), and includes Antoinette R. Petkov and Lauren E. Dunn (M&A and Private Equity) and Sabrina K. Glavota (Technology and Life Sciences Transactions).
Contacts
Capabilities
Suggested News & Insights
Sidley Represents Werewolf Therapeutics in Merger with Ambros Therapeutics and Concurrent US$150 Million Private PlacementAugust 21, 2026Sidley Represents Stone Point Capital in Acquisition of Ever.Ag’s Risk Management BusinessAugust 20, 2026Sidley Represents Clearlake Capital Group in Its Investment in Databricks’ US$5 Billion Funding RoundAugust 19, 2026Sidley Represents Ridgeview Partners in Its Proposed £545 Million Acquisition of Pinewood TechnologiesAugust 19, 2026Mind the Gap: Delaware Court of Chancery’s Clarification of the Implied Covenant’s Contractual Gap-Filling RoleAugust 18, 2026Sidley Earns Three Finalist Recognitions in The American Lawyer Industry Awards 2026August 17, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory